These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose]. Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419 [TBL] [Abstract][Full Text] [Related]
8. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes. Welborn TA Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188 [No Abstract] [Full Text] [Related]
9. Type 2 diabetes: glycemic targets and oral therapies for older patients. Lardinois CK Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974 [TBL] [Abstract][Full Text] [Related]
10. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance]. Sakamoto N; Tajima N Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421 [No Abstract] [Full Text] [Related]
11. [Inhibitors of alpha-glucosidase]. Toeller M Journ Annu Diabetol Hotel Dieu; 1991; ():203-12. PubMed ID: 1886331 [No Abstract] [Full Text] [Related]
12. [Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor]. MMW Fortschr Med; 2000 Jul; 142(26-27):54-5. PubMed ID: 10929491 [No Abstract] [Full Text] [Related]
13. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Scott LJ; Spencer CM Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834 [TBL] [Abstract][Full Text] [Related]
15. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy]. Kellerer M; Jakob S; Linn T; Haslbeck M MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337 [No Abstract] [Full Text] [Related]
16. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673 [TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468 [TBL] [Abstract][Full Text] [Related]
18. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Scheen AJ Drugs; 2003; 63(10):933-51. PubMed ID: 12699398 [TBL] [Abstract][Full Text] [Related]
19. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus. Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342 [TBL] [Abstract][Full Text] [Related]